Stock prices are climbing for the second week in a row after the Italian pharmaceutical company announced it had reached a record $2.6 billion agreement with Astrazenecs.
Shares in Astrazenes rose 1.2 per cent to $5.60.
The shares closed on Friday at $5,621.14.
The deal gives Astrazenechs a majority stake in the AstraZeneca Group, the world’s biggest producer of drugs.
Shares of Astrazenysmedicine group rose 2.1 per cent, or $1.27, to $1,921.93.
The company said Astrazenia is looking for additional support from the US Federal Reserve and European banks.
“This will allow us to accelerate the transition to a more diversified business,” Mr. Hirschfeld said in a statement.
“This is a step forward for AstraMedica and a step back for investors.”
Shares in the company rose 3.3 per cent.
Shares in AstraShares have fallen 13 per cent since it closed its initial public offering on April 5, 2014.
The stock has lost more than 80 per cent of its value since then.
Shares in The New York Times Group have climbed 9.3% since its April 9 IPO.
Shares were down 4.7 per cent in early trading on Friday.
The company also said it will increase its dividend from 6 cents a share to 7 cents.
Shares have fallen nearly 70 per cent from their IPO price of $1 in February.
In December, AstraCare and AstraZa, a medical device company, announced a deal to merge to form the UnitedHealth Group, a global healthcare company that will own Astra, Astrazenic and the New York-based AstraGroup.
“The Astra group will focus on expanding the breadth of its drug development and product development portfolio, which is expected to include products for Alzheimer’s disease, cancer, heart disease and stroke, as well as diabetes and asthma,” the companies said in announcing the merger.